Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic LeukemiaStephan A. Grupp, Hidefumi Hiramatsu, Gregory A. Yanik et al.|Blood|2018Cited by 94
Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)Stephan A. Grupp, Michael A. Pulsipher, Theodore W. Laetsch et al.|Blood|2016Cited by 83
Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene ExpressionDavid A. Jacobsohn, Michael A. Pulsipher, Michael R. Loken et al.|Transplantation and Cellular Therapy|2018Cited by 44
HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell AplasiaMichael W. Boyer, Jennifer Willert, Sonali Chaudhury et al.|Blood|2020Cited by 8
ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II StudyMichael W. Boyer, Jennifer Willert, Sonali Chaudhury et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1